Use of modified RECIST criteria to improve response assessment in targeted therapies: Challenges and opportunities

Cancer Biology and Therapy

Volumn 9, Issue 1, 2010, Pages

  Rosen, Mark A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Choi criteria; RECIST; Renal cell carcinoma; Response assessment; Targeted therapy; Tumor enhancement; VEGFR inhibition

Indexed keywords

CEDIRANIB; IODINATED CONTRAST MEDIUM; SUNITINIB;

CANCER SURVIVAL; CLINICAL ASSESSMENT; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DRUG RESPONSE; HUMAN; KIDNEY CARCINOMA; METASTASIS; METHODOLOGY; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGRESSION FREE SURVIVAL; RESPONSE EVALUATION CRITERIA IN SOLID TUMOR; PROGNOSIS; TREATMENT OUTCOME;

HUMANS; PROGNOSIS; TREATMENT OUTCOME;

EID: 85046915802     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.9.1.10716     Document Type: Note

References (26)

1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47.
2. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-16.
3. Therasse P, Eisenhauer EA, Verweij J. RECIST revisited: a review of validation studies on tumour assessment. Eur J Cancer 2006; 42:1031-9.
4. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G. Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 2005; 11:5223-32.
5. Tombal B, Rezazadeh A, Therasse P, Van Cangh PJ, Vande Berg B, Lecouvet FE. Magnetic resonance imaging of the axial skeleton enables objective measurement of tumor response on prostate cancer bone metastases. Prostate 2005; 65:178-87.
6. Gronlund B, Hogdall C, Hilden J, Engelholm SA, Hogdall EV, Hansen HH. Should CA-125 response criteria be preferred to response evaluation criteria in solid tumors (RECIST) for prognostication during second-line chemotherapy of ovarian carcinoma? J Clin Oncol 2004; 22:4051-8.
7. Heelan R. Staging and response to therapy of malignant pleural mesothelioma. Lung Cancer 2004; 45:59-61.
8. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004; 15:257-60.
9. Tahara M, Ohtsu A, Hironaka S, Boku N, Ishikura S, Miyata Y, et al. Clinical impact of criteria for complete response (CR) of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 2005; 35:316-23.
10. Yoshida S, Miyata Y, Ohtsu A, Boku N, Shirao K, Shimada Y. Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer. Gastric Cancer 2000; 3:128-33.
11. Hillman SL, An MW, O'Connell MJ, Goldberg RM, Schaefer P, Buckner JC, et al. Evaluation of the optimal number of lesions needed for tumor evaluation using the response evaluation criteria in solid tumors: a north central cancer treatment group investigation. J Clin Oncol 2009; 27:3205-10.
12. Schwartz LH, Mazumdar M, Brown W, Smith A, Panicek DM. Variability in response assessment in solid tumors: effect of number of lesions chosen for measurement. Clin Cancer Res 2003; 9:4318-23.
13. Chojniak R, Yu LS, Younes RN. Response to chemotherapy in patients with lung metastases: how many nodules should be measured? Cancer Imaging 2006; 6:107-12.
14. Erasmus JJ, Gladish GW, Broemeling L, Sabloff BS, Truong MT, Herbst RS, et al. Interobserver and intraobserver variability in measurement of nonsmall-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003; 21:2574-82.
15. Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep 2005; 7:307-11.
16. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007; 25:1760-4.
17. Chamberlain MC. Pseudoprogression in glioblastoma. J Clin Oncol 2008; 26:4359.
18. Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, et al. Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 2008; 10:361-7.
19. Ichihara E, Kiura K, Takigawa N, Omori M, Aoe M, Tanimoto M, et al. Pseudoprogression of lung cancer after concomitant chemoradiotherapy. Jpn J Clin Oncol 2008; 38:140-2.
20. Boonsirikamchai P, Podoloff DA, Choi H. Imaging of gastrointestinal stromal tumors and assessment of benefit from systemic therapy. Hematol Oncol Clin North Am 2009; 23:35-48.
21. Linton KM, Taylor MB, Radford JA. Response evaluation in gastrointestinal stromal tumours treated with imatinib: misdiagnosis of disease progression on CT due to cystic change in liver metastases. Br J Radiol 2006; 79:40-4.
22. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: Evolving Considerations for PET response criteria in solid tumors. J Nucl Med 2009; 50:122-50.
23. Miller E, Metser U, Avrahami G, Dvir R, Valdman D, Sira LB, et al. Role of 18F-FDG PET/CT in staging and follow-up of lymphoma in pediatric and young adult patients. J Comput Assist Tomogr 2006; 30:689-94.
24. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDGPET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005; 11:2785-808.
25. Nathan P, Vinayan A, Stott D, Juttla J, Goh V. CT response assessment combining reduction in both size and arterial phase density correlates with time to progression in metastatic renal cancer patients treated with targeted therapies. Cancer Biol Ther 2010; In press.
26. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753-9. In press